arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AGIOS PHARMACEUTICALS, INC.

AGIO
$32.25 ▲ +0.29 (+0.91%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

AGIOS PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield
Revenue Growth 259.3%
Op. Margin -247.1%
ROIC -8.5%
FCF / Share $-0.98
Trailing P/E
Price / Book 1.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.74M
↑ +259.3%
Net Income Profit after all expenses
$-99.11M
↓ -11.0%
Operating Margin Operating profit as % of sales
-247.1%
↓ -560.8%
FCF / Share Free cash flow per share
$-0.98
↑ +51.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters